Category: Science

xoma-logo

XOMA Type 2 Diabetes Drug Fails to Meet End Point in Phase 2 Trials

XOMA Ltd. announced that its phase 2b trial of XOMA 052 in type 2 diabetes patients did not achieve the primary endpoint of reduction of HbA1c after six monthly treatments with XOMA 052 compared to placebo. Biological activity of XOMA 052 supporting its potential...
0 Shares
gsk-logo

GSK Type 1 Diabetes Drug, Otelixizumab, Fails in Phase 3 Study

GlaxoSmithKline and Tolerx, Inc's Investigatinal immunotherapy, Otelixizumab, for type 1 diabetes failed to meet primary end point in the Phase 3 DEFEND-1 study. Otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide...
0 Shares
Mount Sinai School of Nedicine - logo.jpg

Brain Insulin May be a Cause of Type 2 Diabetes and Obesity

Researchers from Mount Sinai School of Medicine have discovered a novel function of brain insulin, indicating that impaired brain insulin action may be the cause of the unrestrained lipolysis that initiates and worsens type 2 diabetes in humans...
0 Shares

Robotic Drug May Prove a Good Treatment for Diabetic Foot Ulcers

Harvard University and Hebrew University scientists have developed a low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns. Several proteins, called growth factors, have been found to speed up the healing process, however purifying these growth factor proteins is very expensive, and they do not last long on the injured site....
0 Shares

Link Found Between Type 1 Diabetes and Enterovirus Infection

While the causes and triggers of type 1 diabetes remain unknown, researchers from Australia have found a link between type 1 diabetes and enteroviruses, which can lead to cold, flu and even meningitis. The researchers conducted an analysis of a number of studies and found that children with type 1 diabetes are almost 10 times more likely...
0 Shares
JDRF New Logo

JDRF and Eli Lilly to Fund Regenerative Medicine Research for Type 1 Diabetes

JDRF and Eli Lilly signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate the insulin-producing cells destroyed by the disease. The goal of this research agreement is to understand how selected cells can be reprogrammed in order to convert them into insulin-producing cells in the body. This research is an example of regenerative medicine...
0 Shares